Cyclomenol

Cyclomenol

SCHEMBL2109474

Cc1cc(C)c(C2CCCCC2)c(O)c1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 9/20 0.43
CNR2 P34972 9/20 0.43
PSMB5 P28074 1/20 0.41
TAS1R3 Q7RTX0 2/20 0.41
TAS1R1 Q7RTX1 2/20 0.41
TAS1R2 Q8TE23 2/20 0.41
NR1I2 O75469 1/20 0.41
KDM4B O94953 1/20 0.41
CHRM1 P11229 1/20 0.41
TBXA2R P21731 1/20 0.41
ADRA1A P35348 1/20 0.41
DOHH Q9BU89 1/20 0.41
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
SELL P14151 1/20 0.38
SELP P16109 1/20 0.38
SELE P16581 1/20 0.38
ACHE P22303 1/20 0.38
UGT2B17 O75795 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11701041 0.98 CNR1 (0.41) CNR1CNR2PSMB5TAS1R3TAS1R1
SCHEMBL2048645 0.90 SELL (0.42) CNR1CNR2TAS1R3TAS1R1TAS1R2
SCHEMBL5358900 0.90 CNR2 (0.50) CNR1CNR2PSMB5NR1I2KDM4B
SCHEMBL1452171 0.86 PSMB5 (0.47) CNR1CNR2PSMB5TAS1R3TAS1R1
SCHEMBL2724194 0.86 PSMB5 (0.47) CNR1CNR2PSMB5TAS1R3TAS1R1
SCHEMBL29446963 0.85 GPR55 (0.44) CNR1CNR2CHRM1TBXA2RADRA1A
SCHEMBL16009497 0.85 GPR55 (0.44) CNR1CNR2CHRM1TBXA2RADRA1A
SCHEMBL8004809 0.83 PSMB5 (0.44) PSMB5TAS1R3TAS1R1TAS1R2NR1I2
SCHEMBL16010483 0.82 GPR55 (0.45) CNR1CNR2CHRM1TBXA2RADRA1A
SCHEMBL28221870 0.81 CNR2 (0.41) CNR1CNR2PSMB5NR1I2KDM4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-0192130-B1 CORROSION INHIBITOR COMPOSITION HENKEL CORPORATION (a Delaware corp.) (US) 1990-06-27 EP claimed
WO-2025129358-A1 STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES INTELGENX CORP. (CA) 2025-06-26 WO disclosed
US-20250017879-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF Bio Logic Crop Science S.L. (ES) 2025-01-16 US disclosed
EP-4427745-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF Bio Logic Crop Science, S.L. (ES) 2024-09-11 EP disclosed
US-11766364-B2 Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents ETHICON, INC. (US) 2023-09-26 US disclosed
WO-2023079206-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF Bio Logic Crop Science S.L. (ES) 2023-05-11 WO disclosed
US-11452641-B2 Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents ETHICON, INC. (US) 2022-09-27 US disclosed
US-20220296422-A1 Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents ETHICON, INC. (US) 2022-09-22 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
EP-0745701-B1 Process for regenerating synthetic diaphragms BASF AG (DE) 1998-12-09 EP disclosed
EP-0745701-A1 Process for regenerating synthetic diaphragms BASF AKTIENGESELLSCHAFT (DE) 1996-12-04 EP disclosed
US-4902830-A CORROSION INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 1990-02-20 US disclosed
EP-0294641-A2 Polyaralkylated hydroxybenzamides, process for their preparation and their use BAYER AG (DE) 1988-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017879-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF SARS1, ACE2, PHOSPHO1 CNR1 3462/4885CNR2 2769/4885PSMB5 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.